SCHEMBL951739

SCHEMBL951739

CC1(C)SCN[C@H]1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.35
APLNR P35414 1/20 0.33
ARG1 P05089 1/20 0.33
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190446 1.00 HTT (0.35) HTTAPLNRARG1KMT2A
SCHEMBL950964 1.00 HTT (0.35) HTTAPLNRARG1KMT2A
Allylamine SCHEMBL27651104 0.85 ARG1 (0.30) ARG1
Allylamine SCHEMBL27651106 0.85 ARG1 (0.30) ARG1
SCHEMBL13534665 0.84
Valine SCHEMBL16004731 0.83 SLC7A5 (0.46)
Gamma-Aminobutyric Acid SCHEMBL1828323 0.82 LMNA (0.44) ARG1KMT2A
SCHEMBL5694169 0.81 HTT (0.31) HTT
SCHEMBL1770442 0.79 ARG1 (0.38) HTTAPLNRARG1KMT2A
SCHEMBL6290400 0.79 ARG1 (0.38) HTTAPLNRARG1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346026-B1 MICROORGANISM PRODUCING 5'-INOSINIC ACID AND PROCESS FOR PRODUCING 5'-INOSINIC ACID USING THE SAME CJ CHEILJEDANG CORP (KR) 2009-04-01 EP claimed
CN-1406273-A Microorganism producing 5'-inosinic acid and process for producing 5'-inosinic acid using the same CHEIL JEDANG CORP (KR) 2003-03-26 CN claimed
EP-3061828-B1 METHOD FOR PRODUCING TARGET SUBSTANCE AJINOMOTO KK (JP) 2024-08-28 EP disclosed
US-11965198-B2 Method for producing target substance by bacterial fermentation AJINOMOTO CO., INC. (JP) 2024-04-23 US disclosed
CN-117802187-A Process for producing purine compounds 味之素株式会社 2024-04-02 CN disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
EP-3861109-A1 METHOD FOR PRODUCING TARGET SUBSTANCE BY BACTERIAL FERMENTATION AJINOMOTO CO., INC. (JP) 2021-08-11 EP disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 US disclosed
WO-2021067439-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 WO disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 US disclosed
WO-2020071538-A1 METHOD FOR PRODUCING TARGET SUBSTANCE BY BACTERIAL FERMENTATION AJINOMOTO CO., INC. (JP) 2020-04-09 WO disclosed
CN-1406273-A Microorganism producing 5'-inosinic acid and process for producing 5'-inosinic acid using the same CHEIL JEDANG CORP (KR) 2003-03-26 CN disclosed
US-20030032150-A1 Process for producing optically active (4r)-1,3-tiazolidine-4-carboxylic acid MITSUBISHI GAS CHEMICAL CO., INC. (JP) 2003-02-13 US disclosed
US-6211212-B1 DRUGS WITH AMIDE AND ESTER GROUPS AS ENZYME INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-03 US disclosed
US-6022885-A Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-08 US disclosed
EP-0970062-A2 PYRROLIDINE AND THIAZOLE DERIVATIVES WITH METALLO-BETA-LACTAMASE INHIBITORY PROPERTIES SMITHKLINE BEECHAM PLC (GB) 2000-01-12 EP disclosed
WO-1998040056-A2 PYRROLIDINE AND THIAZOLE DERIVATIVES WITH METALLO-BETA-LACTAMASE INHIBITORY PROPERTIES SMITHKLINE BEECHAM PLC (GB) 1998-09-17 WO disclosed
US-4775675-A Thiazolidinecarboxylic acid derivatives and treatment of liver diseases therewith BIOGAL GYOGYSZERGYAR (HU) 1988-10-04 US disclosed
CN-86104085-A The preparation method of Thiazolidinecarboxylacid acid derivatives 1987-04-22 CN disclosed
EP-0206197-A1 5,5-Dimethyl-thiazolidin-4(S)-carboxylic-acid derivatives, method for their preparation and medicines containing them BIOGAL GYOGYSZERGYAR (HU) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR HTT 2094/4885APLNR 1226/4885ARG1 2742/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR HTT 2094/4885APLNR 1226/4885ARG1 2742/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR HTT 2094/4885APLNR 1226/4885ARG1 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.